

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 November 2007 (29.11.2007)

PCT

(10) International Publication Number
WO 2007/135036 A1

(51) International Patent Classification:
C07C 231/12 (2006.01) C07C 237/24 (2006.01)
C07C 231/18 (2006.01)

Gamerschwangerstr. 2, 89584 Ehingen (DE). SCHMID,
Rolf [DE/DE]; Talstr. 37, 88487 Baltringen (DE).

(21) International Application Number:
PCT/EP2007/054728

(74) Agent: HAMMANN, Heinz; CD Patents, Binger Strasse
173, 55216 Ingelheim am Rhein (DE).

(22) International Filing Date: 15 May 2007 (15.05.2007)

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR,
LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
06114182.6 18 May 2006 (18.05.2006) EP

(71) Applicant (for all designated States except US):
BOEHRINGER INGELHEIM INTERNATIONAL
GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim
am Rhein (DE).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL,
PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



(72) Inventors; and

(75) Inventors/Applicants (for US only): LINZ, Guenter
[DE/DE]; Eschenweg 6, 88441 Mittelbiberach (DE).
KRAEMER, Gerd [DE/DE]; Auenweg 38a, 88436
Eberhardzell (DE). LEUTER, Zeno A. [DE/DE]; Johann
v. Schnitzer Str. 22, 88250 Weingarten (DE). OS-
TERMEIER, Markus [DE/DE]; Saudengasse 6, 88400
Biberach (DE). RALL, Werner [DE/DE]; Beethovenstr.
33, 88441 Mittelbiberach (DE). OCHS, Claudia [DE/DE];

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF PREPARING CHIRAL CYCLIC β -AMINOCARBOXAMIDES



(57) Abstract: The present invention encompasses a process for preparing compounds of formula (1), wherein a compound of general formula (2) is reacted in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of general formula (1) and wherein A and R¹ - R⁴ are defined as in claim 1.

WO 2007/135036 A1

Method of preparing chiral cyclic β -aminocarboxamides

The invention relates to a new method of preparing chiral cyclic β -aminocarboxamides. β -Aminocarboxamides are synthesis components which are of value in organic synthesis
 5 for building peptidomimetic structures.


Background to the invention

A method of preparing the salts of chiral, substituted cyclic β -aminoesters is described in US 6,835,841. In this method, a cyclic β -enaminoester which is formally obtainable by
 10 reacting a cyclic β -ketoester with an amine is hydrogenated in the presence of a platinum catalyst under hydrogen pressure, while an acid, for example acetic acid, is added in an excess in relation to the hydrogenation substrate. The method described cannot readily be applied to the synthesis of chiral cyclic β -aminocarboxamides, particularly if the nitrogen of the enamine is substituted by a 1-phenylethyl group, for example. In this case, under the
 15 known conditions, hydrogenation of the aromatic ring also occurs, with the result that the hydrogenolytic cleaving of the chiral auxiliary to form the free β -aminocarboxamides becomes impossible.

The aim of the present invention is to provide a method for the direct preparation of cyclic
 20 β -aminocarboxamides with a high diastereoselectivity and yield.

Detailed description of the invention

This aim is achieved by the process according to the invention for preparing compounds of formula (1),




25

wherein

A denotes C₄₋₁₀cycloalkyl or 5-10 membered heterocycloalkyl, the latter containing a heteroatom or a group of heteroatoms, selected from among -O-, -NR^c- and -S(O)_n-, and R¹ and R² each independently denote hydrogen or a group selected from among C₁₋₈alkyl, C₃₋₈cycloalkyl, C₄₋₁₂cycloalkylalkyl, 5-6 membered heteroaryl and 3-8 membered heterocycloalkyl, optionally substituted by one or more identical or different R^a and/or R^b,
 5 or
 R¹ and R² together with the nitrogen atom to which they are bound form a 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, this ring system optionally being substituted by one or more identical or different R^a and/or R^b, and
 10 R³ denotes C₆₋₁₀aryl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different R^a and/or R^b, and
 R⁴ denotes hydrogen or a C₁₋₆alkyl optionally substituted by one or more identical or different R^a and/or R^b, or
 R³ and R⁴ together with the carbon atom to which they are bound form a C₃₋₁₀cycloalkyl or
 15 3-14 membered heterocycloalkyl, while this ring may optionally be fused to an aryl or heteroaryl and the resulting ring system may optionally be substituted by one or more identical or different R^a and/or R^b, and
 n denotes 0, 1 or 2, and
 each R^a is independently selected from among C₁₋₆alkyl, 2-6 membered heteroalkyl,
 20 C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₆cycloalkylalkyl, C₆₋₁₀aryl, C₇₋₁₆arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-8 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, and
 each R^b denotes a suitable group and is independently selected from among -OR^c, C₁₋₃-haloalkyloxy, -OCF₃, -SR^c, -NR^cR^c, -ONR^cR^c, -N(OR^c)R^c, -N(R^c)NR^cR^c, halogen, -CF₃,
 25 -CN, -NC, -OCN, -SCN, -NO, -NO₂, -N₃, -S(O)R^c, -S(O)OR^c, -S(O)₂R^c, -S(O)₂OR^c,
 -S(O)NR^cR^c, -S(O)₂NR^cR^c, -OS(O)R^c, -OS(O)₂R^c, -OS(O)₂OR^c, -OS(O)NR^cR^c,
 -OS(O)₂NR^cR^c, -C(O)R^c, -C(O)OR^c, -C(O)SR^c, -C(O)NR^cR^c, -C(O)N(R^c)NR^cR^c,
 -C(O)N(R^c)OR^c, -C(NR^c)NR^cR^c, -C(NOH)R^c, -C(NOH)NR^cR^c, -OC(O)R^c, -OC(O)OR^c,
 -OC(O)SR^c, -OC(O)NR^cR^c, -OC(NR^c)NR^cR^c, -SC(O)R^c, -SC(O)OR^c, -SC(O)NR^cR^c,
 30 -SC(NR^c)NR^cR^c, -N(R^c)C(O)R^c, -N[C(O)R^c]₂, -N(OR^c)C(O)R^c, -N(R^c)C(NR^c)R^c,
 -N(R^c)N(R^c)C(O)R^c, -N[C(O)R^c]NR^cR^c, -N(R^c)C(S)R^c, -N(R^c)S(O)R^c, -N(R^c)S(O)OR^c,

- $-N(R^c)S(O)_2R^c$, $-N[S(O)_2R^c]_2$, $-N(R^c)S(O)_2OR^c$, $-N(R^c)S(O)_2NR^cR^c$, $-N(R^c)[S(O)_2]_2R^c$,
 $-N(R^c)C(O)OR^c$, $-N(R^c)C(O)SR^c$, $-N(R^c)C(O)NR^cR^c$, $-N(R^c)C(O)NR^cNR^cR^c$,
 $-N(R^c)N(R^c)C(O)NR^cR^c$, $-N(R^c)C(S)NR^cR^c$, $-[N(R^c)C(O)]_2R^c$, $-N(R^c)[C(O)]_2R^c$,
 $-N\{[C(O)]_2R^c\}_2$, $-N(R^c)[C(O)]_2OR^c$, $-N(R^c)[C(O)]_2NR^cR^c$, $-N\{[C(O)]_2OR^c\}_2$,
 5 $-N\{[C(O)]_2NR^cR^c\}_2$, $-[N(R^c)C(O)]_2OR^c$, $-N(R^c)C(NR^c)OR^c$, $-N(R^c)C(NOHR^c)R^c$,
 $-N(R^c)C(NR^c)SR^c$ and $-N(R^c)C(NR^c)NR^cR^c$, and
 each R^c independently denotes hydrogen or C_{1-6} alkyl,
 while a compound of general formula (2)




- 10 is hydrogenated in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of general formula (1).

In one aspect of the invention the method described above is characterised in that the hydrogenation is carried out without any addition of acids.


15

In another aspect the invention relates to the method described herein before wherein A denotes C_{4-7} cycloalkyl.

- In another aspect the invention relates to a method wherein a compound of general formula
 20 (2a)




is hydrogenated in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of general formula **(1a)**

**(1a)**


- 5 In another aspect the invention relates to the method described herein before wherein platinum(IV)-dioxide is used as catalyst.

In another aspect the invention relates to a method wherein a compound of general formula

(3)**(3)**

10


is reacted with a primary amine of general formula **(4)**

**(4)**

in the presence of a dehydrating agent or solvent to form a compound of general formula **(2)**.

15

In another aspect the invention relates to a method as described herein before wherein a compound of general formula **(5)**


**(5)**

is intramolecularly cyclised under basic conditions in the presence of a solvent to form a compound of general formula **(3)**, wherein

X denotes a 1-7 membered alkylene bridge in which a methylene group may be replaced by a heteroatom or a group of heteroatoms selected from among $-O-$, $-NR^c-$ and $-S(O)_n-$.


5

In another aspect the invention relates to a method wherein a compound of general formula **(1)** is reacted in the presence of palladium or palladium(II)-hydroxide on charcoal and a solvent under hydrogen pressure to form a compound of general formula **(6)**

**(6)**

10


In another aspect the invention relates to a method wherein a compound of general formula **(3a)**

**(3a)**

is reacted with 1-phenylethylamine in the presence of a dehydrating agent or solvent to form a compound of general formula **(2a)**.

15

In another aspect the invention relates to a method wherein a compound of general formula **(5a)**

**(5a)**


is intramolecularly cyclised under basic conditions in the presence of a solvent to form a compound of general formula **(3a)**, wherein

R^1 , R^2 and R^a are as herein before defined.

20


In another aspect the invention relates to a method wherein a compound of general formula (1a) is reacted in the presence of palladium or palladium(II)-hydroxide on charcoal as catalyst and a solvent under hydrogen pressure to form a compound of general formula

5 (6a)



(6a)


In another aspect the invention relates to a method wherein a compound of general formula (2b)



(2b)


10

is hydrogenated in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of general formula (1b)




(1b)

15 In another aspect the invention relates to a method wherein a compound of general formula (2c)



(2c)


is hydrogenated in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of general formula (1c)




(1c)

5


In another aspect the invention relates to compounds selected from among general formulae (2a), (1b) and (1c)



(2a)



(1b)



(1c)

wherein R^1 and R^2 are as herein before defined.

10

Definitions

As used herein, the following definitions apply, unless stated otherwise.

By alkyl are meant in each case saturated straight-chain (unbranched) or branched aliphatic hydrocarbon groups (alkyl group). By the groups defined herein before are meant for example methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and decyl, these terms encompassing all the possible isomeric forms, such as for example n- and iso-propyl for propyl, n-butyl, iso-butyl, sec.-butyl and tert.-butyl for butyl, etc.

Heteroalkyl represents straight-chain (unbranched) or branched aliphatic hydrocarbon chains, which are interrupted by 1 to 3 heteroatoms, while each of the available carbon and nitrogen atoms in the heteroalkyl chain may optionally be substituted independently of one another and the heteroatoms are each independently selected from among O, N and S (e.g. 5 dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, diethylaminomethyl, diethylaminoethyl, diethylaminopropyl, 2-diisopropylaminoethyl, bis-2-methoxyethylamino, [2-(dimethylamino-ethyl)-ethyl-amino]-methyl, 3-[2-(dimethylamino-ethyl)-ethyl-amino]-propyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxy, 10 ethoxy, propoxy, methoxymethyl, 2-methoxyethyl).

Haloalkyl relates to alkyl as herein before defined, in which one or more hydrogen atoms are replaced by halogen atoms such as for example $-CF_3$, $-CHF_2$, $-CH_2F$, $-CF_2CF_3$, $-CHFCH_3$, $-CH_2CF_3$, $-CF_2CH_3$, $-CHFCH_3$, $-CF_2CF_2CF_3$, $-CF_2CH_2CH_3$, $-CHFCH_2CH_3$ and 15 $-CHFCH_2CF_3$.

Halogen refers to fluorine, chlorine, bromine and/or iodine atoms.

By cycloalkyl are meant mono-, bicyclic or bridged bicyclic rings and spiro systems, while 20 the ring system may be a saturated ring or, however, also an unsaturated, non-aromatic ring, which may optionally also contain double bonds, such as for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, spiro[2.5]octane and spiro[3.3]heptane.

Cycloalkylalkyl includes a non-cyclic alkyl as herein before defined wherein a hydrogen 25 atom bound to a carbon atom, usually to a terminal C atom, is replaced by a cycloalkyl group as herein before defined.

Aryl relates to monocyclic or bicyclic rings with at least one aromatic ring and 6 – 12 carbon atoms such as for example phenyl, naphthyl, indanyl and 1,2,3,4- 30 tetrahydronaphthyl.

Arylalkyl includes a non-cyclic alkyl as herein before defined wherein a hydrogen atom bound to a carbon atom, usually to a terminal C atom, is replaced by an aryl group as herein before defined.

- 5 By heteroaryl are meant mono- or bi having at least one aromatic ring which contain, instead of one or more carbon atoms, one or more heteroatoms, which may be identical or different, such as e.g. nitrogen, sulphur or oxygen atoms. Examples include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl and
- 10 triazinyl. Examples of bicyclic heteroaryl groups are indolyl, isoindolyl, benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalyl, cinnolinyl, phthalazinyl, quinazolinyl, benzotriazinyl, indoliziny, oxazolopyridyl, imidazopyridyl, naphthyridinyl, indolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl,
- 15 isobenzotetrahydrofuryl, isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridyl, benzotetrahydrofuryl, benzotetrahydrothienyl, purinyl, benzodioxolyl, triazinyl, phenoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, cumariny, isocumarinyl,
- 20 chromonyl, chromanonyl, pyridyl-*N*-oxide tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocumarinyl, dihydroisocumarinyl, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyrrolyl-*N*-oxide, pyrimidinyl-*N*-oxide, pyridazinyl-*N*-oxide, pyrazinyl-*N*-oxide, quinolinyl-*N*-oxide, indolyl-*N*-oxide, indolinyl-*N*-oxide, isoquinolyl-*N*-oxide, quinazolinyl-*N*-oxide, quinoxalyl-*N*-oxide, phthalazinyl-*N*-oxide, imidazolyl-*N*-oxide, isoxazolyl-*N*-oxide, oxazolyl-*N*-oxide, thiazolyl-*N*-oxide,
- 25 indoliziny-*N*-oxide, indazolyl-*N*-oxide, benzothiazolyl-*N*-oxide, benzimidazolyl-*N*-oxide, pyrrolyl-*N*-oxide, oxadiazolyl-*N*-oxide, thiadiazolyl-*N*-oxide, triazolyl-*N*-oxide, tetrazolyl-*N*-oxide, benzothiopyranyl-*S*-oxide and benzothiopyranyl-*S,S*-dioxide.

Heteroarylalkyl encompasses a non-cyclic alkyl as herein before defined wherein a hydrogen atom bound to a carbon atom, usually to a terminal C atom, is replaced by a heteroaryl group as herein before defined.

- 5 Heterocycloalkyl relates to saturated or unsaturated, non-aromatic mono-, bicyclic or bridged bicyclic rings and spiro systems having 3–14 carbon atoms, which carry heteroatoms, such as nitrogen, oxygen or sulphur, instead of one or more carbon atoms. Examples of such heterocycloalkyl groups are tetrahydrofuryl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazoliny, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, indolinyl, 10 isoindolinyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, homothiomorpholinyl, thiomorpholinyl-*S*-oxide, thiomorpholinyl-*S,S*-dioxide, tetrahydropyranlyl, tetrahydrothienyl, homothiomorpholinyl-*S,S*-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranlyl, tetrahydrothienyl-*S*-oxide, 15 tetrahydrothienyl-*S,S*-dioxide, homothiomorpholinyl-*S*-oxide, 2-oxa-5-azabicyclo[2.2.1]heptane, 8-oxa-3-aza-bicyclo[3.2.1]octane, 3,8-diaza-bicyclo[3.2.1]octane, 2,5-diaza-bicyclo[2.2.1]heptane, 3,8-diaza-bicyclo[3.2.1]octane, 3,9-diaza-bicyclo[4.2.1]nonane, 2,6-diaza-bicyclo[3.2.2]nonane, 1,4-dioxa-spiro[4.5]decane, 1-oxa-3,8-diaza-spiro[4.5]decane and 20 2,6-diaza-spiro[3.3]heptane.

Heterocycloalkylalkyl relates to non-cyclic alkyl as herein before defined, wherein a hydrogen atom bound to a carbon atom, usually to a terminal C atom, is replaced by a heterocycloalkyl group as herein before defined.

25


The use of the symbol "*" indicates that there is a stereogenic centre in the part of the molecule thus marked.

- Features and advantages of the present invention will become apparent from the detailed 30 examples that follow, which illustrate the broad outlines of the invention by way of example, without restricting its scope:


Experimental section

Preparation of cyclic β -ketocarboxamides


- 5 **Scheme A-1** (when using primary amines the products **3** obtained correspond to the products **7** from Scheme A-2)



Scheme A-2



- 10 **Scheme A-3**



wherein

X corresponds to a 1-7 membered alkylene bridge, in which a methylene group may be replaced by a heteroatom or a group of heteroatoms $-O-$, $-NR^c-$ or $-S(O)_n-$, and

- 15 R^a , R^c and n have the meanings given for formula (1).


Cyclic β -ketocarboxamides of the general structure **3** may be prepared from cyclic β -ketocarboxylates **1** by reacting with primary or secondary amines (Scheme A-1).

Alternatively cyclic β -ketocarboxamides may be prepared starting from nucleophilic cyclic enamines **4** (formally obtainable from cyclic ketones and a cyclic secondary amine **B**, e.g. morpholine, pyrrolidine) by reacting with suitable isocyanates **5** and subsequent hydrolysis of the intermediate **6** (**7**, Scheme A-2).

Another way of obtaining cyclic β -ketocarboxamides **3** is through amide formation on a hemiester of a dicarboxylic acid **8** to form the intermediate product **9** which is cyclised in an intramolecular Dieckmann condensation (Scheme A-3).

General Preparation of chiral cyclic β -aminocarboxamides


Scheme B-1



From the β -ketocarboxamides **3** and **7** and using enantiomerically pure primary amines **10**, it is possible to generate chiral cyclic β -enaminocarboxamides **11**, which serve as substrates for diastereoselective hydrogenation (**12**, Scheme B-1).

Scheme B-2

Preparation of chiral cyclic β -aminocarboxamides using (*R*)- or (*S*)-1-phenylethylamine as chiral auxiliary and the subsequent cleaving thereof to obtain the free amino group.



Preferably, chiral primary amines, particularly (*R*)- or (*S*)-1-phenylethylamines are used (**R-11a** or **S-11a**, Scheme B-2) to form the β -enaminocarboxamides **11**. In this way a
 5 diastereomer of high selectivity is preferably formed during hydrogenation under the conditions specified below. Preferably a diastereomeric ratio > 60:40, particularly > 80:20, most particularly preferably > 90:10 is thus obtained.

With reference to structurally similar carboxylates of the compounds **R-11a** and **S-11a** it is
 10 known from the prior art that they can be diastereoselectively hydrogenated by the addition of an excess of acid (in relation to the substrate of the hydrogenation), e.g. acetic acid. However, the application of these reaction conditions to the above substrates **11a** leads to overhydrogenation, i.e. the absorption of hydrogen does not stop after one equivalent of H₂ has been taken up. The phenyl group of the chiral auxiliary is also hydrogenated. This
 15 hydrogenation of phenyl groups is prevented in the method according to the invention by omitting the addition of acid during the hydrogenation of the corresponding β -enaminocarboxamides **11a** in the process according to the invention.

After the diastereoselective reduction the desired diastereomer preferably formed may be
 20 purified by direct crystallisation from a lipophilic solvent such as for example

methylcyclohexane or from polar solvent mixtures such as for example alcohol/water, i.e. the intermediate products *R-12a-1S,2R* or *S-12a-1R,2S* do not have to be precipitated in the form of a salt and have diastereomeric purities of > 99 %.

5 When using (*R*)-1-phenylethylamine as chiral auxiliary the two newly generated stereogenic centres in *R-12a* predominantly have the configuration 1*S*,2*R*, and when (*S*)-1-phenylethylamine is used in *S-12a* the configuration is accordingly 1*R*,2*S*, i.e. in each case there is a *cis* configuration at the ring A (*R-12a-1S,2R* or *S-12a-1R,2S*, Scheme **B-2**). By subsequent hydrogenolytic cleaving of the phenethyl group the corresponding cyclic β-aminocarboxamides *13-1S,2R* or *13-1R,2S* are obtained in enantiomeric purities of >99%.

Suitable solvents used may be both protic and aprotic solvents. Protic solvents include for example water and alcohols, such as e.g. methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, ethyleneglycol and trifluorethanol. The aprotic solvents include inter
15 alia ethers, for example tetrahydrofuran (THF), 2-methyltetrahydrofuran, 1,4-dioxane and dimethoxyethane, carboxamides, such as e.g. dimethylformamide and dimethylacetamide, *N*-methylpyrrolidinone, *N*-ethylpyrrolidinone, dimethylsulphoxide, sulpholane, dimethylpropylurea, acetonitrile, esters of acetic acid, such as e.g. ethyl acetate and isopropyl acetate, ketones, such as acetone, ethylmethylketone and methylisobutylketone,
20 hydrocarbons, such as toluene or methylcyclohexane and mixtures of the above-mentioned solvents.

Dehydrating agents used may be orthoesters such as e.g. trimethyl orthoformate or metal compounds such as e.g. titanium tetraisopropoxide.

25 Suitable hydrogenation catalysts include in particular transition metals such as e.g. palladium, nickel, rhodium, ruthenium and iridium. The metals may also be dispersed on a carrier material. Particularly suitable catalysts are platinum, for example platinum on activated charcoal or also platinum(IV)-dioxide, Raney nickel or palladium, such as for
30 example palladium on activated charcoal.

The hydrogen pressure is in the range from 1 - 150 bar, preferably in the range from 1 - 100 bar and particularly preferably in the range from 1 - 80 bar.

The temperature during hydrogenation is in the range from 0 – 150 °C, preferably in the range from 10 - 100 °C and particularly preferably in the range from 20 – 80 °C.


The amount of hydrogenation catalyst used, based on the hydrogenation substrate, is in the range from 0.01 – 50 wt.%, preferably in the range from 0.05 – 30 wt.%, and particularly preferably in the range from 0.1 – 20 wt.%.

10

The use of the method according to the invention for preparing cyclic β -aminocarboxamides is hereinafter described by way of example, the substituents of the general formulae having the meanings specified herein before. These synthesis examples are intended to illustrate the invention without restricting it to their content and without restricting the scope of the method features to these Examples. Where the preparation of starting compounds has not been described they are commercially available or may be prepared analogously to known compounds or methods described here. Substances described in the literature are prepared according to the published methods of synthesis.

20 Example 1

Preparation of the β -ketocarboxamide **7-a** (Method of synthesis 1):




Methyl cyclopentanone-2-carboxylate **1-a** (400 g) and isopropylamine (860 g) are heated to 160 °C in cyclohexane (4 L) in a pressurised reactor for 3 hours (h). The solvent is evaporated down. Methylcyclohexane (500 mL) is added to the residue and it is heated to 60-70 °C. The reaction mixture is stirred for 16 h at room temperature (RT) and after

25

cooling stirred for a further 2 h at -10 °C. The solid is suction filtered and washed with cold methycyclohexane. 225 g amide **2-a** are obtained.


MS-ESI⁺: 211 (M+H)⁺



- 5 A solution of amide **2-a** (222 g) in tetrahydrofuran (700 mL) is combined with 6 N hydrochloric acid (270 mL) and stirred for 16 h at RT and 11 h at 40-50 °C. After the addition of concentrated hydrochloric acid (74 g) the mixture is stirred for another 16 h at RT, saturated saline solution (500 mL) is added and the salts precipitated are suction filtered. The organic phase is separated off, washed with saturated saline solution
- 10 (250 mL), dried on sodium sulphate and evaporated down several times with toluene. The solid remaining is digested with ethyl acetate (700 mL), the suspension formed is suction filtered and the filtrate is evaporated down. 155 g β-ketocarboxamide **7-a** are obtained.
- MS-ESI⁺: 170 (M+H)⁺

15 Example 2

Preparation of β-ketocarboxamide **7-a** (Method of synthesis 2):




- A solution of *N*-(1-cyclopenten-1-yl)morpholine **4-a** (144 mL) and isopropylisocyanate **5-a** (86.4 mL) in toluene (300 mL) is stirred for 2 h at 70 °C. After cooling to 20 °C, 6 N hydrochloric acid (250 mL) is added with vigorous stirring and thorough cooling. The mixture is stirred for 1.5 h at 20 °C, the precipitated solid is suction filtered and washed
- 20 with toluene (100 mL). The toluene phase is separated off, the aqueous phase is extracted

several times with methylene chloride (in each case 100 mL). The organic phases are combined, dried on sodium sulphate and evaporated down (crude product A). The solid suction filtered is digested 3 times with methylene chloride (in each case 100 mL), the combined methylene chloride phases are dried and the solvent is evaporated down (crude product B).

The combined crude products A and B are distilled under reduced pressure. 102 g β -ketocarboxamide **7-a** are obtained. (B.p.: 150 °C at 0.1 mbar)
MS-ESI⁺: 170 (M+H)⁺


10 Example 3a

Preparation of β -ketocarboxamide **7-a** (Method of synthesis 3):



Monomethyl adipate **8-a** (2.56 kg) in toluene (21.5 L) and dimethylformamide (30 mL) are refluxed. Within 0.5 h thionyl chloride (1.22 L) is added dropwise (large amounts of gas given off). The mixture is refluxed for a further 1.6 h and then toluene (13 L) is distilled off under slightly reduced pressure. After cooling to 20 °C toluene (10 L) is added, the mixture is cooled to 6 °C and a solution of 2-propylamine (2.83 kg) in toluene (3 L) is added, so that the temperature does not exceed 13 °C. It is stirred for 16 h at RT and the precipitated 2-propylamine hydrochloride is filtered off. The filtrate is combined with activated charcoal (600 g), filtered and the solvent is evaporated down. 4.2 kg of an oil are obtained which solidifies on cooling. The crude product (**9-a**) contains residual amounts of toluene and is used in the next step without any further purification.

MS-ESI⁺: 202 (M+H)⁺




Potassium-*tert.*-butoxide (1.07 kg) in toluene (20 L) is refluxed. A solution of the crude product **9-a** (1.61 kg) in toluene (10 L) is added to this solution, the mixture is refluxed for

2 h and in this time toluene (6 L) is distilled off. Toluene (3 L) is added and distilled off again (4 L). After cooling to 17 °C 6 N hydrochloric acid (1.67 L) is added and the precipitated potassium chloride is filtered through a suction filter lined with activated charcoal. The filtrate is evaporated down and the residue is crystallised from ethyl acetate/methylcyclohexane. 774 g β -ketocarboxamide **7-a** are obtained. Another 252 g β -ketocarboxamide **7-a** can be isolated from the activated charcoal filter residue by extraction with tetrahydrofuran.

MS-ESI⁺: 170 (M+H)⁺

10 Example 3b

Preparation of the β -ketocarboxamide **7-a** (Method of synthesis 3):



i) Preparation of acid chloride

15 Monomethyl adipate **8-a** (20 kg) in toluene (180 L) and dimethylformamide (300 mL) are heated to 70 °C. Thionyl chloride (16.34 kg) is metered in within 1 h. The mixture is rinsed with toluene (10 L) and the reaction mixture is stirred for 1 h at 70 °C. Then toluene (50 L) is distilled off under reduced pressure.

ii) Amide formation

20 The acid chloride solution is cooled to 15 °C. At 15 to 25 °C a solution of isopropylamine (18.45 kg) in toluene (30 L) is metered in. It is rinsed with toluene (10 L) and the reaction mixture is stirred for 30 min at 20 °C. It is heated to 40 °C and demineralised water (18 L)

is added. The aqueous phase is separated off. 60 L solvent are distilled off from the organic phase under reduced pressure.


iii) Cyclisation

Sodium-tert.-amylate (66.02 kg, 25% in toluene) in toluene (80 L) and tert.-amylalcohol
5 (80 L) are heated to 100 °C. The amide solution is added to this solution at 100 °C within
1 h. It is rinsed with toluene (20 L) and the suspension is stirred for 1 - 2 h at 95 - 100 °C.
It is cooled to 30 ° - 40 °C and diluted with demineralised water (30 L). At 30 to 40 °C
hydrochloric acid (18.97 kg, 30%, industrial grade) is added and the mixture is rinsed with
demineralised water (6 L). The aqueous phase is separated off. 282 L solvent are distilled
10 off from the organic phase under reduced pressure.

The product solution is heated to 50 °C and at 40 - 50 °C diluted with methylcyclohexane
(160 L). Within 2 h the mixture is cooled to 4 °C and stirred for another 30 min at this
temperature. The product is centrifuged off and washed with a mixture of
methylcyclohexane (20 L) and toluene (20 L). The product is dried at 40 °C. 15.4 kg
15 product **7-a** are obtained.


Example 4a

Preparation of the cyclic β -enaminocarboxamide **R-11a-a**




20 A solution of β -ketocarboxamide **7-a** (11.3 g) and (*R*)-1-phenylethylamine (9 g) in toluene
is evaporated down at 60 - 70 °C under reduced pressure using the rotary evaporator.
Toluene is added until no more water goes over azeotropically. The solvent is then
evaporated down completely. The residue is combined with methylcyclohexane (150 mL)
and heated to 70 °C. After cooling the mixture is stirred for 2 h at 0 °C, the solid is suction
25 filtered and washed with cold methylcyclohexane. 13.5 g β -enaminocarboxamide **R-11a-a**
are obtained.

MS-ESI⁺: 273 (M+H)⁺

Example 4bPreparation of the cyclic β -enaminocarboxamide **R-11a-a**

- 5 β -Ketocarboxamide **7-a** (15 kg) in toluene (105 L) is heated to 105 °C. At this temperature (*R*)-1-phenylethylamine (11.82 kg) is added and the mixture is rinsed with 15 L toluene. It is refluxed using the water separator until no more water separates off. The mixture is cooled to 30 °C and demineralised water (15 L) is added. The aqueous phase is separated off. Under reduced pressure 105 L toluene are distilled off from the organic phase. Then
- 10 methylcyclohexane (75 L) is added at 50 °C and 30 L solvent are again distilled off under reduced pressure. 7.5 L tert.-butylmethylether are added to the residue at 55 °C and the mixture is cooled to 43 °C. It is inoculated and cooled to 15 °C within 1 h. After 30 min stirring at 15 °C the product is centrifuged off, washed with methylcyclohexane (30 L) and dried at 40 °C in the drying cupboard. 17.3 kg product **R-11a-a** are obtained.

15

Example 5aPreparation of the cyclic β -aminocarboxamide **R-12a-a-1S,2R**


- A solution of the β -enaminocarboxamide **R-11a-a** (108 g) in absolute ethanol (1 L) is
- 20 hydrogenated for 3 h in the presence of platinum(IV)-dioxide (6 g) at 20 °C under a hydrogen pressure of 5 bar. The catalyst is filtered off and the solution is evaporated down. The crude product obtained (1*S*,2*R*:1*R*,2*S* = 94:6, HPLC) is dissolved in methylcyclohexane (500 mL), filtered clear, cooled to -19 °C, the precipitate is suction

filtered and the filter cake is washed with cold methycyclohexane. 80 g β -aminocarboxamide **R-12a-a-1S,2R** are obtained. (1S,2R:1R,2S > 99:1, HPLC) MS-ESI⁺: 275 (M+H)⁺

- 5 Analogously to the process described above, the hydrogenation of the β -enaminocarboxamide **R-11a-a** is carried out in methanol in the presence of platinum(IV)-dioxide at 30 °C under a hydrogen pressure of 20 bar until the uptake of hydrogen stops.

Example 5b


- 10 Preparation of the cyclic β -aminocarboxamide **R-12a-a-1S,2R**



- A solution of the β -enaminocarboxamide **R-11a-a** (50 g) in methanol (250 mL) is hydrogenated in the presence of platinum(IV)-dioxide (0.5 g) and activated charcoal (5 g) at 20 °C under a hydrogen pressure of 60 psi. The reaction is monitored using thin layer chromatography. After the reaction has ended the catalyst is filtered off and washed with 50 mL methanol (diastereoselectivity: 1S,2R:1R,2S = 96:4, HPLC). 200 mL of methanol are distilled off and 250 mL of n-heptane are added. 150 mL solvent are distilled off azeotropically. Another 200 mL n-heptane are added and again 100 mL of solvent are distilled off azeotropically. The mixture is cooled to 45 °C and inoculated. It is cooled to 20 °C and stirred for 30 min at this temperature. The mixture is suction filtered and washed with n-heptane. 37.5 g β -aminocarboxamide **R-12a-a-1S,2R** (1S,2R:1R,2S > 99.5:0.5, HPLC) are obtained.

Example 6a

- 25 Preparation of the cyclic free β -aminocarboxamide **13-a-1S,2R** [cispentacin-isopropylamide, (1S,2R)-2-amino-1-cyclopentanecarboxylic acid isopropylamide]



A solution of the β -aminocarboxamide **R-12a-a-1S,2R** (82.5 g) in methanol (700 mL) is hydrogenated for 6 h in the presence of palladium(II)-hydroxide on activated charcoal (8 g, 20 wt.%) at 50 °C under a hydrogen pressure of 4 bar. The catalyst is filtered off and the solution is evaporated down. (1*S*,2*R*)-2-amino-1-cyclopentanecarboxylic acid-isopropylamide **13-a-1S,2R** is obtained as an oil, which crystallises out (1*S*,2*R*:1*R*,2*S* > 99:1, chiral HPLC).


MS-ESI⁺: 171 (M+H)⁺

10 Analogously to the preparation of (1*S*,2*R*)-2-amino-1-cyclopentanecarboxylic acid isopropylamide **13-a-1S,2R** the corresponding (1*R*,2*S*)-2-amino-1-cyclopentanecarboxylic acid-isopropylamide **13-a-1R,2S** is prepared using (*S*)-1-phenylethylamine.

MS-ESI⁺: 171 (M+H)⁺

15 **Example 6b**

Preparation of the cyclic free β -aminocarboxamide **13-a-1S,2R** [cispentacin-isopropylamide, (1*S*,2*R*)-2-amino-1-cyclopentanecarboxylic acid isopropylamide]



20 A solution of the β -aminocarboxamide **R-12a-a-1S,2R** (30 g) in methanol (300 mL) is hydrogenated in the presence of palladium on activated charcoal (3 g, 10 wt.%) at 40 °C under a hydrogen pressure of 60 psi. The catalyst is filtered off and the solution is evaporated down. 18.2 g (1*S*,2*R*)-2-amino-1-cyclopentanecarboxylic acid isopropylamide **13-a-1S,2R** is obtained as an oil that crystallises out (1*S*,2*R*:1*R*,2*S* > 99:1, chiral HPLC).

General preparation of salts

The salts of compounds according to the invention are prepared by dissolving the compound in a suitable solvent, such as e.g. an acetic acid ester, or in a suitable mixture of solvents, such as e.g. an alcohol and a lipophilic solvent, such as e.g. methylcyclohexane or toluene, and adding a solution of an organic or inorganic acid in a suitable solvent or mixture of solvents or by directly adding an organic or inorganic acid. The crystalline salts formed are filtered off or centrifuged and dried.

10 **Example 7a**

Preparation of the hydrochloride

9.5 g **13-a-1S,2R** are dissolved in 120 mL ethyl acetate. At a temperature of 40 – 50 °C 5.58 mL of a 10 molar solution of hydrogen chloride in ethanol is added. The suspension is stirred for 30 min at 50 °C, cooled to 20 °C and suction filtered. It is washed with 20 mL ethyl acetate and dried at 40 °C in the circulating air dryer. 9.5 g hydrochloride salt are obtained.

Melting point: 183 – 184° C

Example 7b

20 Preparation of the benzenesulphonic acid salt

4.9 g **13-a-1S,2R** are dissolved in 10 mL ethanol and 40 mL methylcyclohexane. 4.55 g benzenesulphonic acid are added. The suspension formed is stirred for 1.5 h and suction filtered. It is washed with 10 mL methylcyclohexane and dried at 40 °C in the circulating air dryer. 8.05 g benzenesulphonic acid salt are obtained.

25 Melting point: 152 – 153° C

Example 7c


The p-toluenesulphonic acid salt is prepared analogously to Example 7b.

Melting point: 155 - 156°C

30

Claims

1. Method of preparing a compound of general formula (1),



5 wherein

A denotes C₄₋₁₀cycloalkyl or 5-10 membered heterocycloalkyl, the latter containing a heteroatom or a group of heteroatoms, selected from among -O-, -NR^c- and -S(O)_n-, and

R¹ and R² each independently denote hydrogen or a group selected from among C₁₋₈alkyl, C₃₋₈cycloalkyl, C₄₋₁₂cycloalkylalkyl, 5-6 membered heteroaryl and 3-8 membered

10 heterocycloalkyl, optionally substituted by one or more identical or different R^a and/or R^b, or

R¹ and R² together with the nitrogen atom to which they are bound form a 3-14 membered heterocycloalkyl or 5-12 membered heteroaryl, this ring system optionally being substituted by one or more identical or different R^a and/or R^b, and

15 R³ denotes C₆₋₁₀aryl or 5-12 membered heteroaryl, optionally substituted by one or more identical or different R^a and/or R^b, and

R⁴ denotes hydrogen or a C₁₋₆alkyl optionally substituted by one or more identical or different R^a and/or R^b, or

20 R³ and R⁴ together with the carbon atom to which they are bound form a C₃₋₁₀cycloalkyl or 3-14 membered heterocycloalkyl, while this ring may optionally be fused to an aryl or heteroaryl and the resulting ring system may optionally be substituted by one or more identical or different R^a and/or R^b, and


n denotes 0, 1 or 2, and

each R^a is independently selected from among C₁₋₆alkyl, 2-6 membered heteroalkyl,

25 C₁₋₆haloalkyl, C₃₋₁₀cycloalkyl, C₄₋₁₆cycloalkylalkyl, C₆₋₁₀aryl, C₇₋₁₆arylalkyl, 5-12 membered heteroaryl, 6-18 membered heteroarylalkyl, 3-8 membered heterocycloalkyl and 4-14 membered heterocycloalkylalkyl, and

- each R^b denotes a suitable group and is independently selected from among $-OR^c$, C_{1-3} haloalkyloxy, $-OCF_3$, $-SR^c$, $-NR^cR^c$, $-ONR^cR^c$, $-N(OR^c)R^c$, $-N(R^c)NR^cR^c$, halogen, $-CF_3$, $-CN$, $-NC$, $-OCN$, $-SCN$, $-NO$, $-NO_2$, $-N_3$, $-S(O)R^c$, $-S(O)OR^c$, $-S(O)_2R^c$, $-S(O)_2OR^c$, $-S(O)NR^cR^c$, $-S(O)_2NR^cR^c$, $-OS(O)R^c$, $-OS(O)_2R^c$, $-OS(O)_2OR^c$, $-OS(O)NR^cR^c$, $-OS(O)_2NR^cR^c$, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)SR^c$, $-C(O)NR^cR^c$, $-C(O)N(R^c)NR^cR^c$, $-C(O)N(R^c)OR^c$, $-C(NR^c)NR^cR^c$, $-C(NOH)R^c$, $-C(NOH)NR^cR^c$, $-OC(O)R^c$, $-OC(O)OR^c$, $-OC(O)SR^c$, $-OC(O)NR^cR^c$, $-OC(NR^c)NR^cR^c$, $-SC(O)R^c$, $-SC(O)OR^c$, $-SC(O)NR^cR^c$, $-SC(NR^c)NR^cR^c$, $-N(R^c)C(O)R^c$, $-N[C(O)R^c]_2$, $-N(OR^c)C(O)R^c$, $-N(R^c)C(NR^c)R^c$, $-N(R^c)N(R^c)C(O)R^c$, $-N[C(O)R^c]NR^cR^c$, $-N(R^c)C(S)R^c$, $-N(R^c)S(O)R^c$, $-N(R^c)S(O)OR^c$, $-N(R^c)S(O)_2R^c$, $-N[S(O)_2R^c]_2$, $-N(R^c)S(O)_2OR^c$, $-N(R^c)S(O)_2NR^cR^c$, $-N(R^c)[S(O)_2]_2R^c$, $-N(R^c)C(O)OR^c$, $-N(R^c)C(O)SR^c$, $-N(R^c)C(O)NR^cR^c$, $-N(R^c)C(O)NR^cNR^cR^c$, $-N(R^c)N(R^c)C(O)NR^cR^c$, $-N(R^c)C(S)NR^cR^c$, $-[N(R^c)C(O)]_2R^c$, $-N(R^c)[C(O)]_2R^c$, $-N\{[C(O)]_2R^c\}_2$, $-N(R^c)[C(O)]_2OR^c$, $-N(R^c)[C(O)]_2NR^cR^c$, $-N\{[C(O)]_2OR^c\}_2$, $-N\{[C(O)]_2NR^cR^c\}_2$, $-[N(R^c)C(O)]_2OR^c$, $-N(R^c)C(NR^c)OR^c$, $-N(R^c)C(NOH)R^c$, $-N(R^c)C(NR^c)SR^c$ and $-N(R^c)C(NR^c)NR^cR^c$, and


each R^c independently denotes hydrogen or C_{1-6} alkyl, wherein a compound of general formula (2)



- is hydrogenated in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of general formula (1).


2. Method according to claim 1, characterised in that the hydrogenation is carried out without any addition of acids.
3. Method according to claim 1 or 2, wherein the ring A denotes C_{4-7} cycloalkyl.

4. Method according to one of claims 1 to 3, wherein a compound of general formula (2a)



(2a)

is hydrogenated in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of general formula (1a)




(1a)

5


5. Method according to one of claims 1 to 4, wherein platinum(IV)-dioxide is used as catalyst.

10 6. Method according to one of claims 1 to 3, or 5, characterised in that a compound of general formula (3)



(3)


is reacted with a primary amine of general formula (4)



(4)

15 in the presence of a dehydrating agent or solvent to form a compound of general formula (2).


7. Method according to claim 6, characterised in that a compound of general formula (5)




is cyclised intramolecularly under basic conditions in the presence of a solvent to form a compound of general formula (3), wherein

X denotes a 1-7 membered alkylene bridge, in which a methylene group may be replaced by a heteroatom or a group of heteroatoms selected from among -O-, -NR^c- and -S(O)_n-.

8. Method according to claim 7, characterised in that a compound of general formula (1) is reacted in the presence of palladium or palladium(II)-hydroxide on charcoal and a solvent under hydrogen pressure to form a compound of general formula (6)




9. Method according to claim 4, characterised in that a compound of general formula (3a)



is reacted with 1-phenylethylamine in the presence of a dehydrating agent or solvent to form a compound of general formula (2a).

10. Method according to claim 9, characterised in that a compound of general formula

(5a)



(5a)


is cyclised intramolecularly under basic conditions in the presence of a solvent to form
 5 a compound of general formula (3a), wherein
 R¹, R² and R^a are as herein before defined for formula (1).

11. Method according to claim 4, characterised in that the compound of general formula

(1a) is reacted in the presence of palladium or palladium(II)-hydroxide on charcoal as


10 catalyst and a solvent under hydrogen pressure to form a compound of general formula

(6a)



(6a)

12. Method according to claim 4, wherein a compound of general formula (2b)




(2b)

15


is hydrogenated in the presence of a catalyst and a solvent under hydrogen pressure to

form a compound of general formula **(1b)**



(1b)


13. Method according to claim 4, wherein a compound of general formula **(2c)**



(2c)


5

is hydrogenated in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of general formula **(1c)**




(1c)


10 14. Compounds selected from among general formulae **(2a)**, **(1b)** and **(1c)**



(2a)



(1b)



(1c)

wherein **R¹** and **R²** are as herein before defined.

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/054728

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07C231/12 C07C231/18 C07C237/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AUDEBERT, P. ET AL: "Electrochemical evidence for intramolecular reactions of the electrogenerated cation-radicals of some amidoenamines" JOURNAL OF ELECTROANALYTICAL CHEMISTRY , 389(1-2), 215-18 CODEN: JECHES; ISSN: 0368-1874, 1995, XP002399691 page 216; figure 1; compound 6 ----- -/--	14

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

12 July 2007

Date of mailing of the international search report

19/07/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fitz, Wolfgang

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/054728

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NOTEBERG D ET AL: "Synthesis of enantiomerically pure cis and trans 2-aminocyclopentanecarboxylic acids. Use of proline replacements in potential HIV-protease inhibitors" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 53, no. 23, 9 June 1997 (1997-06-09), pages 7975-7984, XP004105735 ISSN: 0040-4020 * Schema 2 und Schema 3 * -----	1,14
A	US 2004/082795 A1 (DEERBERG JOERG ET AL) 29 April 2004 (2004-04-29) claim 1 examples 1-5 -----	1,14
A	WO 2004/085378 A (MERCK & CO. INC; XIAO, YI; ARMSTRONG, JOSEPH, D., III; KRKA, SHANE, W) 7 October 2004 (2004-10-07) claim 1 examples 1,3-6 -----	1,14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/054728

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2004082795	A1	29-04-2004	NONE
WO 2004085378	A	07-10-2004	AU 2004223885 A1 07-10-2004
			CA 2518435 A1 07-10-2004
			CN 1761642 A 19-04-2006
			EP 1606243 A1 21-12-2005
			JP 2006521354 T 21-09-2006